Establishment Labs (NASDAQ:ESTA) Director Sells $2,446,125.00 in Stock

Establishment Labs Holdings Inc. (NASDAQ:ESTA) Director Quiros Juan Jose Chacon sold 37,500 shares of the firm’s stock in a transaction dated Tuesday, April 14th. The shares were sold at an average price of $65.23, for a total value of $2,446,125.00. Following the transaction, the director directly owned 1,182,504 shares in the company, valued at approximately $77,134,735.92. This represents a 3.07% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Quiros Juan Jose Chacon also recently made the following trade(s):

• On Wednesday, March 25th, Quiros Juan Jose Chacon sold 3,575 shares of Establishment Labs stock. The shares were sold at an average price of $60.08, for a total transaction of $214,786.00.
• On Monday, March 23rd, Quiros Juan Jose Chacon sold 33,925 shares of Establishment Labs stock. The shares were sold at an average price of $60.39, for a total transaction of $2,048,730.75.

Establishment Labs Trading Down 3.2%

NASDAQ ESTA traded down $2.10 during trading on Thursday, hitting $64.51. 839,456 shares of the company’s stock traded hands, compared to its average volume of 508,999. The stock has a fifty day moving average of $67.07 and a two-hundred day moving average of $63.96. The company has a debt-to-equity ratio of 10.51, a current ratio of 3.04 and a quick ratio of 2.00. Establishment Labs Holdings Inc. has a 12-month low of $28.67 and a 12-month high of $83.31. The firm has a market cap of $1.90 billion, a P/E ratio of -37.07 and a beta of 1.08.

Establishment Labs (NASDAQ:ESTA) last posted its quarterly earnings results on Tuesday, February 24th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.13. Establishment Labs had a negative net margin of 24.19% and a negative return on equity of 201.79%. The business had revenue of $64.62 million during the quarter, compared to analyst estimates of $63.80 million. During the same period in the prior year, the business posted ($1.19) earnings per share. The company’s revenue was up 45.2% on a year-over-year basis. As a group, sell-side analysts expect that Establishment Labs Holdings Inc. will post -2.41 EPS for the current year.

Hedge Funds Weigh In On Establishment Labs

Several hedge funds and other institutional investors have recently modified their holdings of ESTA. Quarry LP purchased a new position in shares of Establishment Labs during the third quarter valued at about $34,000. Kestra Advisory Services LLC purchased a new position in shares of Establishment Labs during the fourth quarter valued at about $47,000. State of Wyoming purchased a new position in shares of Establishment Labs during the third quarter valued at about $71,000. Osaic Holdings Inc. increased its position in shares of Establishment Labs by 900.0% during the second quarter. Osaic Holdings Inc. now owns 2,000 shares of the company’s stock valued at $85,000 after buying an additional 1,800 shares during the period. Finally, MV Capital Management Inc. purchased a new position in shares of Establishment Labs during the fourth quarter valued at about $146,000. Hedge funds and other institutional investors own 72.91% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have issued reports on ESTA. Needham & Company LLC upped their price target on shares of Establishment Labs from $84.00 to $86.00 and gave the company a “buy” rating in a research report on Tuesday, February 24th. Stephens upped their price target on shares of Establishment Labs from $85.00 to $90.00 and gave the company an “overweight” rating in a research report on Wednesday, February 25th. JPMorgan Chase & Co. boosted their price objective on shares of Establishment Labs from $71.00 to $80.00 and gave the company an “overweight” rating in a research report on Wednesday, December 17th. Wall Street Zen cut shares of Establishment Labs from a “buy” rating to a “hold” rating in a research report on Saturday, March 28th. Finally, Mizuho boosted their price objective on shares of Establishment Labs from $90.00 to $100.00 and gave the company an “outperform” rating in a research report on Wednesday, February 25th. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $86.86.

Establishment Labs Company Profile

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.